GlassScriptPhysician profile
Matheson A Taylor
NPI 1174267314
$1,902.57
in general payments reported to CMS, 2019-2025
19 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $103 · 2023: $184 · 2024: $64.97 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.50 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $312.65 | 2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $289.55 | 2025 | |
| Tactile Systems Technology INC | $288.90 | 2022-2024 | Flexitouch Plus, Entre Plus |
| Regeneron Healthcare Solutions, INC. | $176.13 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $155.23 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $105.97 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $92.89 | 2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $70.97 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $64.34 | 2025 | |
| Ardelyx, INC. | $49.73 | 2025 | Ibsrela |
| Novo Nordisk INC | $47.82 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $46.80 | 2025 | Givlaari |
| Boston Scientific Corporation | $46.58 | 2024 | Varithena Administration Pack |
| Celltrion USA INC. | $44.32 | 2025 | Vegzelma |
| Lilly USA, LLC | $35.55 | 2025 | Omvoh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $29.22 | 2025 | Suflave |
| Biohaven Pharmaceutical Holding Company LTD. | $16.07 | 2022 | |
| Mirum Pharmaceuticals, INC. | $15.39 | 2025 | Livmarli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.46 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matheson Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.